CLAIMS

1. A composition comprising

(i) a fimbrial H (FimH) polypeptide, or a functional fragment thereof, or

a nucleic acid molecule that encodes a FimH polypeptide, or a functional fragment thereof,

wherein said FimH polypeptide is stabilized by a donor-strand peptide of FimG (DsG);

(ii) each of the following conjugates:

a conjugate comprising a carrier protein covalently bound to a saccharide comprising Formula O25b, wherein n is an integer from 1 to 100 in the formula thereof,

a conjugate comprising a carrier protein covalently bound to a saccharide comprising Formula O1A, wherein n is an integer from 1 to 100 in the formula thereof,

a conjugate comprising a carrier protein covalently bound to a saccharide comprising Formula O2, wherein n is an integer from 1 to 100 in the formula thereof, and

a conjugate comprising a carrier protein covalently bound to a saccharide comprising Formula O6:K2, Formula O6:K13, Formula O6:K15, or Formula O6:K54, wherein n is an integer from 1 to 100 in the formula thereof; and

(iii) an adjuvant.

2. The composition of claim 1,

wherein n is an integer from 31 to 90 in the Formula thereof for each of said saccharides, and wherein the composition further comprises:

a conjugate comprising a carrier protein covalently bound to a saccharide comprising Formula O8, wherein *n* is an integer from 31 to 90 in the Formula thereof for said saccharide, and

a conjugate comprising a carrier protein covalently bound to a saccharide comprising Formula O9 or O9a, wherein *n* is an integer from 31 to 90 in the Formula thereof for said saccharide.

3. The composition of claim 1, wherein n is an integer from 31 to 90 in the formula thereof for each of said saccharides.

4. The composition according to claim 3, further comprising one or more conjugates having a saccharide selected from the group consisting of Formula O16, Formula O17, Formula O18A, Formula O18ac, Formula O18A1, Formula O18B, Formula O18B1, and Formula O75, wherein n is an integer from 31 to 90 in the formula thereof for each saccharide.

5. The composition according to claim 1, wherein the carrier protein is selected from the group consisting of CRM_{197}, diphtheria toxin fragment B (DTFB), DTFB C8, Diphtheria toxoid (DT), tetanus toxoid (TT), fragment C of TT, pertussis toxoid, cholera toxoid, exotoxin A from Pseudomonas aeruginosa, detoxified Exotoxin A of *P. aeruginosa* (EPA), maltose binding protein (MBP), detoxified hemolysin A of *S. aureus*, clumping factor A, clumping factor B, Cholera toxin B subunit (CTB), *Streptococcus pneumoniae* Pneumolysin or detoxified variants thereof, *C. jejuni* AcrA, and *C. jejuni* natural glycoproteins.

6. The composition according to claim 1, wherein the polypeptide is *E. coli* fimbrial H (FimH).

7. The composition according to claim 6, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 2.

8. The composition according to claim 6, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 3

9. The composition according to claim 6, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 27, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, and SEQ ID NO: 113.

10. The composition of claim 6, wherein the polypeptide comprises an amino acid sequence having at least 70% identity to a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, and SEQ ID NO: 113.

11. The composition according to claim 6, wherein the polypeptide comprises a fragment of FimH.

12. The composition according to claim 11, wherein the polypeptide comprises a lectin domain of FimH.

13. The composition according to claim 6, wherein the polypeptide is complexed with a FimC polypeptide or a fragment thereof.

14. The composition according to claim 1, wherein the polypeptide further comprises a linker.

15. The composition according to claim 1, wherein the adjuvant comprises QS-21.

16. The composition according to claim 1, wherein the adjuvant comprises MPLA.

17. The composition according to claim 1, wherein the adjuvant comprises QS-21 and MPLA.

18. The composition according to claim 1, comprising a nucleic acid molecule that encodes a FimH polypeptide, or a functional fragment thereof, wherein the nucleic acid is RNA.

19. Use of the composition according to any one of claims 1-18 in the manufacture of a medicament for eliciting an immune response against *Escherichia coli* in a mammal, wherein an effective amount of the medicament is to be administered to the mammal.

20. The composition according to any one of claims 1-18 for use as a medicament for eliciting an immune response against E. coli in a mammal.